drugset

drugset / Trial / NCT02254044

Dose Escalation of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck or Esophagus

NCT02254044 ↗

Phase 1 Terminated 7 enrolled Boehringer Ingelheim

NaSingle-groupOpen-labelTreatment

Summary

maximum tolerated dose (MTD), safety, pharmacokinetics, efficacy of bivatuzumab mertansine

Timeline

Start: 2003-10
Primary completion: 2004-11
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	bivatuzumab mertansine	Unknown	—	Intravenous

Indications